Becaplermin is a medicine used to help wounds heal faster. It works by encouraging new blood vessels to grow near the wound, which helps the healing process.
Every report comes from a Lived member, sent anonymously.
Have you tried Becaplermin for Diabetic Foot?
Becaplermin, sold as Regranex, is a prescription gel used to help heal certain leg and foot ulcers in people with diabetes. It is meant for diabetic neuropathic ulcers: open sores that develop when nerve damage from diabetes dulls feeling in the feet, so pressure and small injuries go unnoticed and a wound forms. To qualify, the ulcer must reach below the skin into the tissue underneath, and the leg must have an adequate blood supply. Becaplermin is an add-on to good ulcer care, not a replacement for it. That care includes debridement (a clinician cutting away dead and unhealthy tissue), keeping weight off the ulcer with special shoes, a walker, crutches or a wheelchair, and treating any infection. The gel has not been shown to help pressure ulcers (bedsores) or venous ulcers, which are caused by poor circulation in the leg veins. It has not been studied in shallow ulcers or in diabetic ulcers caused mainly by poor blood flow, and it is not used on surgical wounds closed with stitches or staples. Its safety and effectiveness have not been established in people under 16.
Platelet-derived growth factor is a protein the body uses to repair wounds. It draws repair cells into a wound, prompts them to multiply and helps build granulation tissue, the moist, red new tissue that fills a wound from the bottom up. Becaplermin is a lab-made copy of one form of this protein, produced in yeast. Spread directly on a cleaned ulcer, it adds to this repair signal in a chronic wound that has stopped healing on its own. The gel cannot overcome the problems that keep diabetic ulcers open in the first place, such as continued pressure on the foot, infection or poor circulation. That is why it works only alongside the rest of ulcer care.
Becaplermin comes as a 0.01% gel in a 15-gram tube. It is for use on the skin only and must not be used in or near the eyes, mouth or vagina. The daily amount depends on the size of the ulcer: the care team measures the ulcer's greatest length and width and uses a formula to set how long a strip of gel to squeeze out. Because the goal is for the ulcer to shrink, its size should be rechecked every 1 to 2 weeks and the amount recalculated. The gel is applied once a day. After washing hands, the measured strip is squeezed onto a clean, firm surface such as wax paper, then spread in a thin, even layer over the whole ulcer with a clean cotton swab, tongue depressor or similar tool. The tip of the tube should not touch the ulcer or any other surface. The ulcer is then covered with gauze moistened with saline (sterile salt water). About 12 hours later, the dressing comes off, the ulcer is rinsed with saline or water to remove the gel, and a fresh moist dressing without gel goes on for the rest of the day. Using more than the prescribed amount, or applying it more often than once every 24 hours, is not recommended. The tube is kept in the refrigerator between uses. It should not be frozen or used past the expiration date printed on its sealed end.
Because becaplermin is applied to the ulcer surface, most side effects are local. A red skin rash was the most common one in clinical trials, affecting about 2 in 100 people, although the same rate was seen with a placebo gel. Burning or redness where the gel is applied has also been reported since the drug came to market. Some of these reactions come from irritation or allergy to preservatives in the gel (parabens and m-cresol). Burning, a rash or other new skin changes around the ulcer are worth reporting to the care team. They may pause or stop the gel and, in some cases, arrange patch testing to find the cause.
Becaplermin should not be used on a site where there is a known cancer. Because it encourages cells to multiply and new blood vessels to form, researchers have looked closely for any link with cancer. Cancers in other parts of the body, away from the treated ulcer, have been reported in people who used it, both in a clinical study and after approval. In one follow-up of about 500 trial participants over a median of 20 months, cancer was diagnosed in 2.7% of people who had used becaplermin and 1% of those who had not, a difference that could have arisen by chance. Larger studies of insurance and health records have given mixed results: one found more cancer deaths among people dispensed three or more tubes, while two studies of veterans found no increase. For people who already have cancer, the prescriber should weigh the possible benefit against this uncertain risk. Whether becaplermin interacts with other creams, gels or ointments applied to the ulcer is not known, because this has not been studied, so check with the care team before putting anything else on the wound. There are no data on its use during pregnancy or breastfeeding, so anyone who is pregnant, planning a pregnancy or breastfeeding should discuss it with the prescriber.
Becaplermin works slowly. In the main trials, any difference between becaplermin and a placebo gel usually became visible only after about 10 weeks, and treatment continued for up to 20 weeks. In the largest trial, about half of the ulcers treated with becaplermin plus good ulcer care closed completely within 20 weeks, compared with about a third of those treated with placebo gel. Another trial found no clear advantage over good ulcer care alone. A Cochrane review, which pools the trials, concluded that growth factors such as becaplermin may raise the chance of complete healing, but the trials were small and at risk of bias, and they have not shown fewer amputations. The gel is used once a day until the ulcer heals. If the ulcer has not shrunk by about 30% after 10 weeks, or has not healed by 20 weeks, the care team should reconsider whether to continue. Much of daily life during treatment revolves around the ulcer care itself: keeping weight off the foot, changing dressings, and regular visits for measurement and debridement. Healing is not always the end of the problem. In the trials, about 30% of healed ulcers came back within three months, so the plan for protecting the foot after healing matters too.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Becaplermin, what you've noticed, or ask the community a question.